Galmed Total Current Assets vs Deferred Long Term Liab Analysis

GLMD Stock

USD 2.75 0.05 1.79%

Galmed Pharmaceuticals financial indicator trend analysis is much more than just examining Galmed Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Galmed Pharmaceuticals is a good investment. Please check the relationship between Galmed Pharmaceuticals Total Current Assets and its Deferred Long Term Liab accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.

Total Current Assets vs Deferred Long Term Liab

Total Current Assets vs Deferred Long Term Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Galmed Pharmaceuticals Total Current Assets account and Deferred Long Term Liab. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Galmed Pharmaceuticals' Total Current Assets and Deferred Long Term Liab is 0.18. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of Galmed Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Galmed Pharmaceuticals' Total Current Assets and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Galmed Pharmaceuticals are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Total Current Assets i.e., Galmed Pharmaceuticals' Total Current Assets and Deferred Long Term Liab go up and down completely randomly.

Correlation Coefficient

0.18

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Most indicators from Galmed Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Galmed Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.At present, Galmed Pharmaceuticals' Sales General And Administrative To Revenue is projected to drop slightly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 0.25, whereas Issuance Of Capital Stock is forecasted to decline to about 5.9 M.

	2021	2022	2023	2024 (projected)
Interest Income	562K	297K	375K	747.7K
Net Interest Income	519K	275K	745K	775.1K

Interest Income Net Interest Income

Galmed Pharmaceuticals fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment
Common Stock Shares Outstanding		-0.21	0.68	-0.37	-0.29	-0.21	-0.22	-0.32	0.28	0.37	-0.24	-0.23	-0.42	0.31	-0.19	-0.11	-0.45	0.66	-0.05	-0.36	-0.07	-0.44	-0.19	-0.39	-0.42	-0.47
Total Assets	-0.21		-0.43	0.66	0.58	1.0	0.47	0.42	-0.77	-0.29	0.58	0.76	-0.08	0.15	1.0	0.49	0.66	-0.5	0.53	0.62	0.46	0.15	1.0	0.54	0.08	0.37
Short Long Term Debt Total	0.68	-0.43		-0.64	-0.6	-0.43	-0.51	-0.48	0.37	0.72	-0.55	-0.3	-0.54	0.3	-0.4	-0.38	-0.82	0.98	-0.14	-0.75	-0.3	-0.71	-0.41	-0.67	-0.56	-0.61
Other Current Liab	-0.37	0.66	-0.64		0.78	0.63	0.75	0.26	-0.41	-0.66	0.72	0.38	0.26	-0.19	0.64	0.62	0.82	-0.71	0.27	0.79	0.62	0.28	0.64	0.42	0.46	0.29
Total Current Liabilities	-0.29	0.58	-0.6	0.78		0.53	0.63	0.52	-0.18	-0.6	0.99	0.14	0.16	-0.06	0.56	0.85	0.72	-0.57	0.42	0.7	0.94	0.38	0.57	0.53	0.27	0.51
Total Stockholder Equity	-0.21	1.0	-0.43	0.63	0.53		0.44	0.4	-0.79	-0.27	0.53	0.78	-0.07	0.14	1.0	0.44	0.65	-0.5	0.52	0.61	0.4	0.15	1.0	0.53	0.08	0.35
Other Liab	-0.22	0.47	-0.51	0.75	0.63	0.44		0.11	-0.24	-0.66	0.55	0.21	0.25	-0.03	0.45	0.4	0.78	-0.48	0.19	0.78	0.53	0.39	0.46	0.32	0.37	0.1
Property Plant And Equipment Net	-0.32	0.42	-0.48	0.26	0.52	0.4	0.11		-0.44	-0.09	0.52	0.41	-0.07	0.31	0.42	0.56	0.37	-0.45	0.39	0.27	0.41	0.52	0.42	0.72	-0.15	0.9
Net Debt	0.28	-0.77	0.37	-0.41	-0.18	-0.79	-0.24	-0.44		0.01	-0.15	-1.0	0.11	-0.16	-0.77	-0.06	-0.4	0.46	-0.4	-0.3	-0.01	-0.13	-0.77	-0.52	0.03	-0.42
Retained Earnings	0.37	-0.29	0.72	-0.66	-0.6	-0.27	-0.66	-0.09	0.01		-0.58	0.04	-0.76	0.54	-0.24	-0.45	-0.86	0.69	-0.06	-0.91	-0.43	-0.71	-0.25	-0.15	-0.8	-0.27
Accounts Payable	-0.24	0.58	-0.55	0.72	0.99	0.53	0.55	0.52	-0.15	-0.58		0.11	0.14	-0.03	0.56	0.88	0.68	-0.51	0.46	0.68	0.94	0.36	0.57	0.5	0.24	0.49
Cash	-0.23	0.76	-0.3	0.38	0.14	0.78	0.21	0.41	-1.0	0.04	0.11		-0.15	0.19	0.77	0.04	0.35	-0.39	0.41	0.26	-0.01	0.08	0.76	0.48	-0.08	0.38
Non Current Assets Total	-0.42	-0.08	-0.54	0.26	0.16	-0.07	0.25	-0.07	0.11	-0.76	0.14	-0.15		-0.87	-0.12	-0.03	0.5	-0.49	-0.04	0.52	0.02	0.69	-0.12	-0.24	0.95	0.3
Long Term Debt	0.31	0.15	0.3	-0.19	-0.06	0.14	-0.03	0.31	-0.16	0.54	-0.03	0.19	-0.87		0.18	0.13	-0.21	0.28	0.11	-0.25	0.0	-0.27	0.18	0.46	-0.9	-0.1
Cash And Short Term Investments	-0.19	1.0	-0.4	0.64	0.56	1.0	0.45	0.42	-0.77	-0.24	0.56	0.77	-0.12	0.18		0.48	0.63	-0.48	0.53	0.59	0.45	0.12	1.0	0.54	0.03	0.35
Net Receivables	-0.11	0.49	-0.38	0.62	0.85	0.44	0.4	0.56	-0.06	-0.45	0.88	0.04	-0.03	0.13	0.48		0.55	-0.35	0.43	0.57	0.84	0.26	0.48	0.44	0.09	0.41
Common Stock Total Equity	-0.45	0.66	-0.82	0.82	0.72	0.65	0.78	0.37	-0.4	-0.86	0.68	0.35	0.5	-0.21	0.63	0.55		-0.83	0.27	0.98	0.49	0.69	0.64	0.5	0.58	0.44
Non Current Liabilities Total	0.66	-0.5	0.98	-0.71	-0.57	-0.5	-0.48	-0.45	0.46	0.69	-0.51	-0.39	-0.49	0.28	-0.48	-0.35	-0.83		-0.13	-0.75	-0.25	-0.65	-0.48	-0.67	-0.53	-0.57
Other Current Assets	-0.05	0.53	-0.14	0.27	0.42	0.52	0.19	0.39	-0.4	-0.06	0.46	0.41	-0.04	0.11	0.53	0.43	0.27	-0.13		0.25	0.43	0.17	0.53	0.24	-0.02	0.37
Other Stockholder Equity	-0.36	0.62	-0.75	0.79	0.7	0.61	0.78	0.27	-0.3	-0.91	0.68	0.26	0.52	-0.25	0.59	0.57	0.98	-0.75	0.25		0.51	0.66	0.6	0.39	0.61	0.34
Total Liab	-0.07	0.46	-0.3	0.62	0.94	0.4	0.53	0.41	-0.01	-0.43	0.94	-0.01	0.02	0.0	0.45	0.84	0.49	-0.25	0.43	0.51		0.17	0.46	0.31	0.13	0.36
Property Plant And Equipment Gross	-0.44	0.15	-0.71	0.28	0.38	0.15	0.39	0.52	-0.13	-0.71	0.36	0.08	0.69	-0.27	0.12	0.26	0.69	-0.65	0.17	0.66	0.17		0.12	0.33	0.53	0.67
Total Current Assets	-0.19	1.0	-0.41	0.64	0.57	1.0	0.46	0.42	-0.77	-0.25	0.57	0.76	-0.12	0.18	1.0	0.48	0.64	-0.48	0.53	0.6	0.46	0.12		0.55	0.04	0.35
Short Term Debt	-0.39	0.54	-0.67	0.42	0.53	0.53	0.32	0.72	-0.52	-0.15	0.5	0.48	-0.24	0.46	0.54	0.44	0.5	-0.67	0.24	0.39	0.31	0.33	0.55		-0.24	0.53
Common Stock	-0.42	0.08	-0.56	0.46	0.27	0.08	0.37	-0.15	0.03	-0.8	0.24	-0.08	0.95	-0.9	0.03	0.09	0.58	-0.53	-0.02	0.61	0.13	0.53	0.04	-0.24		0.2
Property Plant Equipment	-0.47	0.37	-0.61	0.29	0.51	0.35	0.1	0.9	-0.42	-0.27	0.49	0.38	0.3	-0.1	0.35	0.41	0.44	-0.57	0.37	0.34	0.36	0.67	0.35	0.53	0.2

Click cells to compare fundamentals

Galmed Pharmaceuticals Account Relationship Matchups

Galmed Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	1.4M	1.4M	1.6M	1.7M	230.8K	219.3K
Total Assets	77.1M	52.4M	36.6M	16.6M	16.6M	15.8M
Other Current Liab	892K	935K	966K	1.0M	830K	673.0K
Total Current Liabilities	6.9M	8.0M	5.9M	3.1M	2.8M	4.0M
Total Stockholder Equity	69.9M	44.2M	30.5M	13.4M	13.9M	13.2M
Property Plant And Equipment Net	709K	570K	551K	337K	125K	118.8K
Net Debt	(15.6M)	(6.7M)	(2.7M)	(2.0M)	(2.8M)	(3.0M)
Retained Earnings	(106.9M)	(135.7M)	(168.2M)	(186.0M)	(193.0M)	(183.3M)
Accounts Payable	6.0M	7.0M	4.9M	2.6M	1.9M	3.2M
Cash	15.9M	6.9M	2.9M	2.0M	2.9M	2.7M
Non Current Assets Total	709K	570K	551K	1.8M	3.4M	3.6M
Cash And Short Term Investments	75.5M	50.9M	34.8M	13.8M	12.6M	12.0M
Net Receivables	827K	812K	1.1M	124K	165K	156.8K
Liabilities And Stockholders Equity	77.1M	52.4M	36.6M	16.6M	16.6M	15.8M
Other Current Assets	28.1M	925K	1.2M	668K	432K	410.4K
Other Stockholder Equity	176.7M	179.5M	198.8M	200.1M	207.1M	135.2M
Total Liab	7.3M	8.2M	6.1M	3.1M	2.8M	4.4M
Property Plant And Equipment Gross	709K	570K	551K	1.3M	1.1M	678.5K
Total Current Assets	76.4M	51.8M	36.1M	14.7M	13.2M	12.6M
Accumulated Other Comprehensive Income	35K	272K	(171K)	(745K)	(454K)	(431.3K)
Property Plant Equipment	194K	709K	570K	337K	387.6K	519.1K
Net Tangible Assets	15.8M	87.9M	69.9M	44.2M	50.8M	38.5M
Short Term Investments	59.6M	43.9M	31.9M	11.8M	9.8M	9.3M
Net Invested Capital	69.9M	44.2M	30.5M	13.4M	13.9M	13.2M
Net Working Capital	69.5M	43.8M	30.2M	11.6M	10.5M	10.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Galmed Pharmaceuticals is a strong investment it is important to analyze Galmed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Galmed Pharmaceuticals' future performance. For an informed investment choice regarding Galmed Stock, refer to the following important reports:

How To Invest In Galmed

Details

Is Galmed Stock a good investment?

Details

What is Galmed Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.

You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

69.72

Return On Assets

(0.29)

Return On Equity

(0.53)

The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Galmed Total Current Assets vs Deferred Long Term Liab Analysis

Total Current Assets vs Deferred Long Term Liab

Total Current Assets vs Deferred Long Term Liab Correlation Analysis

Correlation Coefficient

Total Current Assets

Deferred Long Term Liab

Galmed Pharmaceuticals fundamental ratios Correlations

Galmed Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Galmed Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments

Cash	- 1.0	Net Debt
Other Stockholder Equity	- 0.91	Retained Earnings
Common Stock	- 0.9	Long Term Debt
Long Term Debt	- 0.87	Non Current Assets Total
Common Stock Total Equity	- 0.86	Retained Earnings
Non Current Liabilities Total	- 0.83	Common Stock Total Equity